CHS-0214: Completed Phase III enrollment

Coherus completed enrollment in the double-blind, international Phase III RApsody (CHS-0214-02) trial comparing 50 mg subcutaneous CHS-0214 once weekly vs. 50 mg Enbrel etanercept once weekly for 24 weeks in about 620 patients. The completion of enrollment in CHS-0214-02 and the Phase III RaPsOdy (CHS-0214-04) trial of CHS-0214 to treat chronic plaque psoriasis triggered a $35 million milestone payment to Coherus under a 2013 deal granting Baxter exclusive, worldwide rights to develop and commercialize a biosimilar of Enbrel outside the U.S., Japan and certain Caribbean and Latin American countries (see BioCentury, Sept. 9, 2013).

CHS-0214-02 is enrolling patients who have an inadequate response to methotrexate and are naive to biologic therapies. The study includes an open-label portion evaluating CHS-0214 in patients who achieve at least an ACR20 response. ...